Navigation Links
Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
Date:2/11/2008

COPENHAGEN, Denmark, Feb. 11 /PRNewswire/ -- Santaris Pharma, the Danish biopharmaceutical company developing LNA based RNA medicines, announced today that Keith McCullagh, President and Chief Executive Officer, will be presenting an overview of the company and its goals for 2008 at the Biotechnology Industry Organisation's 10th Annual CEO & Investor Conference in New York, today, Monday February 11th at 12:30 pm, US Eastern Standard Time (18:30 Central European Time). The conference is being held at the Waldorf Astoria Hotel, New York City from February 11th-13th, 2008.

A live webcast of the Santaris Pharma presentation may be accessed from the news section of the company's website, http://www.santaris.com, where it will also be archived and available after the presentation.

About Santaris Pharma

Santaris Pharma is a Danish based clinical-stage biopharmaceutical company. The company was formed in 2003 and currently employs around 100 people. Santaris Pharma has the exclusive rights to LNA technology, a 3rd generation antisense chemistry used to develop new classes of RNA medicines, called RNA Antagonists and microRNA antagonists. Santaris Pharma's RNA Antagonists are targeted against tissue specific mRNAs associated with cancer, metabolic disorders and viral disease. In May 2006 Santaris Pharma completed a Euro 40m second round of equity financing and in December 2007 the Company completed a Euro 20m third round of equity financing. Santaris Pharma has a global partnership with Enzon Pharmaceuticals of New Jersey to co-develop and commercialise a series of Santaris Pharma RNA Antagonists for improving the treatment of cancer. GlaxoSmithKline has options to up to four Santaris Pharma drug candidates targeted against viral disease.

For further information please contact

Randi Krogsgaard, Director Corporate Communications

Direct phone: +45 45179879

Cell: +45
'/>"/>

SOURCE Santaris Pharma
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
5. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2009)...en,s University Belfast are developing new sensors... will help in the fight against the threat of terr...l pads to ,swipe, an individual or crime scene to ...ng instrument that can detect the presence of chem...er decisions to be made in response to terrorist t...
(Date:11/18/2009)...Calif., Nov. 18 Masimo...ry(TM) and Measure-Through Motion and Low-Perfusio...e-based Uni.H.A., one of the largest healthcare Gr...signed a multi-year purchasing agreement for "gold...e agreement offers preferred contract pricing to U...
(Date:11/18/2009)...GA, ON, Nov. 18 /PRNewswire-FirstCall/ - YM BioSci...ences product development company that identifies ...er-related products at various stages of developme... nimotuzumab were presented today in a poster at t...r Therapeutics conference in Boston, Massachusetts...
(Date:11/18/2009)...significantly reduces key cardiac enzymes at multi...ted at American Heart Association 2009 Scientific ... Viron Therapeutics Inc., a biotechnology company ...otein therapeutics derived from pathogens, today r...aluating VT-111 (Serp-1), an anti-inflammatory pro...
Breaking Biology Technology:New technology detects chemical weapons in seconds 2Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products 2Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products 3Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products 4YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING 2YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING 3Viron reports positive Phase II data in Acute Coronary Syndromes (ACS) patients 2Viron reports positive Phase II data in Acute Coronary Syndromes (ACS) patients 3Viron reports positive Phase II data in Acute Coronary Syndromes (ACS) patients 4
...scovery at Rensselaer Polytechnic Institute could ... aircraft, watercraft, and automobiles. , Epoxy c... the design of new jets, planes, and other vehicle...ight, which lowers the overall weight of the vehic...t epoxy composites can be brittle, which is detrim...
...etes Care , , IRVINE, Calif., March 26 On March ... its prestigious global diabetes research award. T...vative G1A(TM) Rapid Diabetes Monitoring Index Te...damage caused by excess sugar in the body. , , (P...26/LA89768 ) , , Diabetes is one of the biggest ...
...URAL FUELS INDUSTRIES, INC. (Pink Sheets: VGPR) to...ir rating for the Company to "Fully Compliant", it... OTC Markets categorizes all securities trading ov... inform investors whether an issuer has made adequ...r. Subsequent to NFI,s recent filing, Pink OTC Ma...
Other Biology Technology:Fitter frames: Nanotubes boost structural integrity of composites 2Frost & Sullivan Award Highlights Opportunity for 'Main Street' Biotech 2Pink OTC Markets Moves Natural Fuels Industries to Top Tier 2
(Date:11/20/2009)...ease (COPD), a respiratory disease commonly known ...leading cause of death worldwide. 600 million peo...to find any real treatment or cure, Grace Parraga ... Western Ontario in London, Canada, is using vario... disease. , Parraga is a scientist in the Im...
(Date:11/20/2009)...researchers report that a class of heart medicatio...mful, effect on the heart, depending on their mole...e journal Circulation Research , found that beta-...ptors on the heart muscle offer the most benefit t...he beta-receptors can actually undermine the struc...
(Date:11/19/2009)..., at the end of the last ice age, North America,s ...conic creatures as mammoths, mastodons, camels, ho... precipitous slide to extinction. , And when the...rsity of large animals equaled or surpassed Africa...entirely novel ecosystem emerged as broadleaved tr...
Breaking Biology News(10 mins):Gaining a better picture of lung disease 2Carvedilol shown to have unique characteristics among beta blockers 2After mastodons and mammoths, a transformed landscape 2After mastodons and mammoths, a transformed landscape 3Why Do African Americans Fare Worse With Cancer 3F Access and Economics Are Only Part of the Story 4697 1Why Do African Americans Fare Worse With Cancer 3F Access and Economics Are Only Part of the Story 4697 2Why Do African Americans Fare Worse With Cancer 3F Access and Economics Are Only Part of the Story 4697 3New Drug Application for Exenatide Once Weekly Accepted for Review by FDA 12927 1New Drug Application for Exenatide Once Weekly Accepted for Review by FDA 12927 2New Drug Application for Exenatide Once Weekly Accepted for Review by FDA 12927 3New Drug Application for Exenatide Once Weekly Accepted for Review by FDA 12927 4New Drug Application for Exenatide Once Weekly Accepted for Review by FDA 12927 5New Drug Application for Exenatide Once Weekly Accepted for Review by FDA 12927 6Diplomat Specialty Pharmacy 3A Only Vendor to Receive URAC Accreditation for Both Disease Management and Drug Therapy Management 50990 1Diplomat Specialty Pharmacy 3A Only Vendor to Receive URAC Accreditation for Both Disease Management and Drug Therapy Management 50990 2Diplomat Specialty Pharmacy 3A Only Vendor to Receive URAC Accreditation for Both Disease Management and Drug Therapy Management 50990 3
...n human stem cell research, producing embryonic-li...ly speed up the development of treatments for life... The discovery made during a project undertaken wi...anch and the Synthecon Corporation in the United S...with an ethical and reliable source of human stem ...
...-threatening infection in the body, a virus such a...ng, with the cell,s outer membrane. Once inside th...kes over, turning the ,host, cell into a factory t...ll out to invade other cells in the body. , Scient...ith a cell,s membrane, infection of the host cell ...
...he San Francisco VA Medical Center (SFVAMC) and th...ave identified six genes associated with lymphocyt...ative bronchitis (OB), the most common cause of lo...rchers hope their results will lead to an earlier,...or chronic lung rejection, as well as greater unde...
Other Biology News:Insight into the processes of 'positive' and 'negative' learners 2Several minute intermediate stage in virus-cell fusion discovered; opportunity for drug development 2Several minute intermediate stage in virus-cell fusion discovered; opportunity for drug development 3Researchers identify genes associated with lung transplant rejection 2
Human MMP-9 / NGAL Complex ELISA Kit from R&D Systems
20X TE buffer *RNase free* from Molecular Probes (Invitrogen)
Sheep Serum from Lifeblood Medical, Inc.
Goat Anti-Human LAIR2 Polyclonal Antibodies, Biotin Conjugated from R&D Systems
Biology Products: